Senthil Sundaram joins Terns Pharmaceuticals as CEO and Board of Directors

Terns Pharmaceuticals, Inc. announced the appointment of Senthil Sundaram as Chief Executive Officer (CEO) and member of the Board of Directors. Prior to joining Terns, Senthil was the Chief Financial Officer of Nightstar Therapeutics plc, a clinical-stage gene therapy company, until it was acquired by Biogen in 2019.

Terns Pharmaceutical is a global biopharmaceutical company committed to discovering and developing molecularly targeted, oral, small molecule drugs to treat liver disease and cancer. They are a $52 million company headquartered in Foster City, CA with 52 employees.